**Indian Pharma Sector Faces Challenges Amid Tariff Uncertainty**
The Indian pharmaceutical industry is navigating a complex landscape marked by price increases, site relocations, and intellectual property (IP) transfers as it grapples with ongoing uncertainties stemming from US tariffs. A recent report by Systematix Research underscores the industry’s need for these strategies to effectively manage the challenges posed by tariff fluctuations, which have led to hesitance among companies to expand their capacities in the US market.
The report indicates that while companies are seeking to adapt to tariff-related pressures, raw material prices, particularly for antibiotics, are experiencing significant corrections. This has prompted customers to destock in order to capitalize on lower prices. Overall, prices for generic active pharmaceutical ingredients (APIs) have stabilized, providing a glimmer of hope for the sector.
Despite the challenges, companies remain cautiously optimistic about exploring new growth avenues and product launches that could mitigate the impact of declining high-value launches. In the contract development and manufacturing organization (CDMO) segment, demand for custom synthesis and CDMO services remains robust, with several firms eyeing opportunities in the GLP-1 market in India and other emerging markets, preparing for immediate launches.
However, the domestic market has seen a decline in demand for anti-infectives, while the development of over-the-counter (OTC) platforms continues to be a strategic focus. The report highlights that the first quarter of FY26 was disappointing, with more companies underperforming than exceeding expectations. Most players in the Indian pharmaceutical sector reported mid-to-high single-digit organic growth, but the US market faced margin pressures due to price erosion.
Among the companies that performed well, Sun Pharma exceeded expectations thanks to reduced operational costs, although its US generics segment underperformed. Pfizer reported a 7% growth, aided by lower operational expenses, while Syngene benefited from higher-than-anticipated licensing income, resulting in improved margins. Conversely, Orchid Pharma struggled with a decline in cephalosporin API volumes due to customer destocking, and Piramal Pharma faced significant challenges in its export business due to competitive pressures from China. Dr. Reddy’s Laboratories experienced weakness in its high-value US generics, impacting its margins, while Divi’s Laboratories reported steady revenue but slightly weaker margins.
In conclusion, the Indian pharmaceutical sector is currently facing short-term uncertainties, yet companies are strategically positioning themselves for long-term growth opportunities.
**FAQ**
**What are the main challenges facing the Indian pharmaceutical industry?**
The Indian pharmaceutical industry is primarily challenged by tariff uncertainties, price erosion, and fluctuating raw material costs, which are affecting growth and profitability.